A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder

Greg Mattingly, Valerie Arnold, Brian Yan, Ming Yu, Brigitte Robertson, Greg Mattingly, Valerie Arnold, Brian Yan, Ming Yu, Brigitte Robertson

Abstract

Objectives: In a previous pivotal study of children and adolescents (aged 6-17 years) with attention-deficit/hyperactivity disorder (ADHD), dose-optimized SHP465 mixed amphetamine salts (MAS) extended-release (12.5-25 mg once daily) was superior to placebo in reducing ADHD symptoms. This study evaluated the efficacy, tolerability, and safety of 6.25 mg SHP465 MAS once daily (one-half the lowest approved dose for adolescents and adults) versus placebo in children aged 6-12 years with ADHD. Methods: Children (aged 6-12 years) with Diagnostic and Statistical Manual of Mental Disorders, Fifth edition-defined ADHD; baseline ADHD-Rating Scale, Fifth Edition, Child, Home Version total scores (ADHD-RS-5-HV-TS) ≥28; and baseline Clinical Global Impressions-Severity scores ≥4 were eligible. Participants received 6.25 mg SHP465 MAS once daily or placebo for 4 weeks. The primary (ADHD-RS-5-HV-TS change from baseline at week 4) and key secondary (Clinical Global Impressions-Improvement [CGI-I] score at week 4) efficacy end points were assessed using linear mixed-effects models for repeated measures. Safety and tolerability assessments included treatment-emergent adverse events (TEAEs) and vital sign changes. Results: Of 89 randomized participants, 83 completed the study (placebo, n = 41; SHP465 MAS, n = 42). At week 4, the least squares mean (95% confidence interval) treatment differences (SHP465 MAS-placebo) were not statistically significant for ADHD-RS-5-HV-TS change (-1.9 [-6.8 to 3.1], p = 0.451; effect size [ES] = 0.17) or CGI-I score (-0.1 [-0.5 to 0.3], nominal p = 0.597; ES = 0.12). The percentage of participants reporting TEAEs was 16.3% with placebo and 24.4% with SHP465 MAS. The most frequently reported TEAEs (placebo; SHP465 MAS) were headache (7.0%; 4.4%) and decreased appetite (4.7%; 2.2%). Minimal increases in blood pressure were observed with SHP465 MAS at the final on-treatment assessment. Conclusions: SHP465 MAS 6.25 mg once daily (one-half the lowest dose approved for adolescents and adults) was well tolerated in children aged 6-12 years but was not superior to placebo in reducing ADHD symptoms, suggesting that this dose of SHP465 MAS was subtherapeutic in this age group. The Clinical Trial Registration number: NCT03325881.

Keywords: SHP465 (Mydayis) mixed amphetamine salts; attention-deficit/hyperactivity disorder (ADHD); children; efficacy; safety and tolerability.

Figures

FIG. 1.
FIG. 1.
Participant disposition. LAR, legally authorized representative; MAS, mixed amphetamine salts.
FIG. 2.
FIG. 2.
Mean ± SD ADHD-RS-5-HV total score (A) and CGI-I score (B) by visit and treatment group, full analysis set. ADHD, attention-deficit/hyperactivity disorder; ADHD-RS-5-HV, ADHD-Rating Scale, Fifth Edition, Child, Home Version; CGI-I, Clinical Global Impressions-Improvement; MAS, mixed amphetamine salts; SD, standard deviation.

References

    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013
    1. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL: Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 29:450–463, 2007
    1. Biederman J, Lopez FA, Boellner SW, Chandler MC: A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 110:258–266, 2002
    1. Brams M, Childress AC, Greenbaum M, Yu M, Yan B, Jaffee M, Robertson B: SHP465 mixed amphetamine salts in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: Results of a randomized, double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 28:19–28, 2018
    1. Canafax DM, Bhanegaonkar A, Bharmal M, Calloway M: Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: Results from two double-blind, multicenter, placebo-controlled clinical trials. BMC Neurol 11:48, 2011
    1. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: Introduction to the ADHD rating scales In: ADHD Rating Scale-5 for Children and Adolescents: Checklists, Norms, and Clinical Interpretation. New York, Guilford Publications, 2016, pp. 1–6
    1. Ermer JC, Shojaei A, Pennick M, Anderson CS, Silverberg A, Youcha SH: Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release. Curr Med Res Opin 23:1067–1075, 2007
    1. Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L: Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 50:395–405, 2011
    1. Frick G, Yan B, Adler LA: Triple-bead mixed amphetamine salts (SHP465) in adults with ADHD: Results of a phase 3, double-blind, randomized, forced-dose trial. J Atten Disord 24:402–413, 2020
    1. Guy W: Clinical Global Impressions. Rockville (Maryland), US Department of Health, Education, and Welfare; Public Health Service; Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, 1976
    1. McCracken JT, Biederman J, Greenhill LL, Swanson JM, McGough JJ, Spencer TJ, Posner K, Wigal S, Pataki C, Zhang Y, Tulloch S: Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry 42:673–683, 2003
    1. Mydayis® (Mixed Salts of a Single-Entity Amphetamine Product): Full Prescribing Information. Lexington (Massachusetts), Shire US, Inc., 2019
    1. Owens JA, Spirito A, McGuinn M: The Children's Sleep Habits Questionnaire (CSHQ): Psychometric properties of a survey instrument for school-aged children. Sleep 23:1043–1051, 2000
    1. Pliszka SR, Browne RG, Olvera RL, Wynne SK: A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 39:619–626, 2000
    1. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ: The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168:1266–1277, 2011
    1. Spencer TJ, Adler LA, Weisler RH, Youcha SH: Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: A randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry 69:1437–1448, 2008
    1. Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R: Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: A 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28:266–279, 2006
    1. Stein MA, Waldman ID, Charney E, Aryal S, Sable C, Gruber R, Newcorn JH: Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol 21:581–588, 2011
    1. Swanson J, Wigal S, Greenhill L, Browne R, Waslick B, Lerner M, Williams L, Flynn D, Agler D, Crowley KL, Fineberg E, Regino R, Baren M, Cantwell D: Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull 34:55–60, 1998
    1. United States Food and Drug Administration: Guidance for industry: How to comply with the Pediatric Research Equity Act. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available at: (accessed March29, 2019)
    1. Weisler RH, Greenbaum M, Arnold V, Yu M, Yan B, Jaffee M, Robertson B: Efficacy and safety of SHP465 mixed amphetamine salts in the treatment of attention-deficit/hyperactivity disorder in adults: Results of a randomized, double-blind, placebo-controlled, forced-dose clinical study. CNS Drugs 31:685–697, 2017
    1. Wigal S, Lopez F, Frick G, Yan B, Robertson B, Madhoo M: A randomized, double-blind, 3-way crossover, analog classroom study of SHP465 mixed amphetamine salts extended-release in adolescents with ADHD. Postgrad Med 131:212–224, 2019
    1. Wigal T, Brams M, Frick G, Yan B, Madhoo M: A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design. Postgrad Med 130:481–493, 2018a
    1. Wigal T, Childress A, Frick G, Yan B, Wigal S, Madhoo M: Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment. Postgrad Med 130:111–121, 2018b

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi